
CHANGES TO THE COMPOSITION OF THE BOARD AND BOARD COMMITTEES

The Board of Directors (the “**Board**”) of OUE Lippo Healthcare Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) wishes to inform the shareholders on the following changes in the composition of the Board and Board Committees:

1. Mr Masato Mohri has resigned as a Non-Independent Non-Executive Director of the Company with effect from 7 May 2019 and accordingly, he shall cease as a member of the Nominating and Remuneration Committee (“**NRC**”) of the Company; and
2. Mr Tadahiro Kiyosu has been appointed by the Board as a Non-Independent Non-Executive Director of the Company and a member of the NRC of the Company with effect from 7 May 2019.

Consequent to the above changes, the Board and the NRC will be reconstituted as follows with effect from 7 May 2019:

Board of Directors

Mr. Lee Yi Shyan	-	<i>Non-Independent Non-Executive Chairman</i>
Mr. Yet Kum Meng	-	<i>Chief Executive Officer / Executive Director</i>
Mr. Tadahiro Kiyosu	-	<i>Non-Independent Non-Executive Director</i>
Mr. Roger Tan Chade Phang	-	<i>Lead Independent Director</i>
Mr. Eric Sho Kian Hin	-	<i>Independent Director</i>
Mr. Jackson Tay Eng Kiat	-	<i>Independent Director</i>
Mr. Johji Sato	-	<i>Independent Director</i>

Nominating and Remuneration Committee

Mr. Roger Tan Chade Phang	-	<i>Chairman</i>
Mr. Lee Yi Shyan	-	<i>Member</i>
Mr. Tadahiro Kiyosu	-	<i>Member</i>
Mr. Eric Sho Kian Hin	-	<i>Member</i>
Mr. Jackson Tay Eng Kiat	-	<i>Member</i>

There will be no changes to the compositions of the Audit and Risk Committee.

The Board would like to take this opportunity to extend its sincere appreciation to Mr Masato Mohri for his invaluable contribution to the Company and the Group and extend its warm welcome to Mr Tadahiro Kiyosu as its newest member.

Further details of Mr Masato Mohri’s cessation and Mr Tadahiro Kiyosu’s appointment which are required to be disclosed pursuant to the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist have been set out in separate announcements released to SGX-ST today.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
7 May 2019

*This announcement has been prepared by the Company and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).